Clinical Trial Update: Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for cabiralizumab in pigmented villonodular synovitis and diffuse-type tenosynovial giant cell tumor; study completed with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pigmented Villonodular Synovitis
• Tenosynovial Giant Cell Tumor

Drugs mentioned

• Cabiralizumab

Snippet

Sponsor: Five Prime Therapeutics, Inc. | Conditions: Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-08-31